Atea Pharmaceuticals (AVIR) EBT Margin (2021)

Atea Pharmaceuticals (AVIR) recorded quarterly EBT Margin of 63.08% in Q4 2021, up 193.68% quarter-over-quarter from 67.34% in Q3 2021.

Atea Pharmaceuticals (AVIR) EBT Margin (2021) Analysis & Trends

Atea Pharmaceuticals' EBT Margin history runs 1 years deep, the most recent figure standing at 63.08% for Q4 2021.

In Q4 2021, EBT Margin changed N/A year-over-year to 63.08%; the TTM figure through Dec 2021 stood at 39.44% (changed N/A YoY), while the FY2021 annual figure was 39.44%, up 6195.0% from the prior year.
EBT Margin was 63.08% for Q4 2021 at Atea Pharmaceuticals, up from 67.34% in the prior quarter.
In the past five years, EBT Margin ranged from a high of 63.08% in Q4 2021 to a low of 67.34% in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	6.40%
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	41.95%
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Atea Pharmaceuticals	347.28 Mn	347.28 Mn	-	-

Download Data